Rajeev S. Samant and Lalita A. Shevde * Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA Keywords: angiogenesis, tumor progression, metastasis, VEGF, angiogenesis inhibitors Received: February 28, 2011; Accepted: March 7, 2011; Published: March 7, 2011; Correspondence: Rajeev S. Samant, e-mail: // Lalita A. Shevde, e-mail: // // Abstract Since angiogenesis is critical for tumor growth and metastasis, anti-angiogenic treatment is a highly promising therapeutic approach. Thus, for over last couple of decades, there has been a robust activity aimed towards the discovery of angiogenesis inhibitors. More than forty anti-angiogenic drugs are being tested in clinical trials all over the world. This review discusses agents that have approved by the FDA and are currently in use for treating patients either as single-agents or in combination with other chemotherapeutic agents.
No takes yet. Share an insight, caveat, or question.
Samant et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: